^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)

i
Other names: ADH4, Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide, ADH-2, All-Trans-Retinol Dehydrogenase [NAD(+)] ADH4, Alcohol Dehydrogenase Class II Pi Chain, Epididymis Secretory Protein Li 4, Alcohol Dehydrogenase 4, Aldehyde Reductase, HEL-S-4
Associations
Trials
30d
Hedyotis diffusa Willd suppresses hepatocellular carcinoma tumor-stromal interactions by inactivating cancer-associated hepatic stellate cells. (PubMed, J Gastrointest Oncol)
We proposed that HDW might interrupt tumor-stromal interaction via ADH4. This study provides a new perspective for the treatment of HCC with HDW, demonstrating the feasibility of ADH4 as an HCC treatment target.
Journal
|
ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
1m
Identification and validation of prognostic genes related to glycolysis and M2 macrophage in hepatocellular carcinoma: an integrated analysis of bulk RNA sequencing and single-cell RNA sequencing. (PubMed, Front Immunol)
RT-qPCR confirmed that PFKFB4, FOXK1, and TKTL1 were upregulated in HCC, while ADH4 and ADH1C were downregulated. Eight prognostic genes were identified, and a risk model was established, providing valuable insights for clinical prognostic prediction and immunotherapy in HCC.
Journal • IO biomarker
|
ADH1C (Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide) • ARL2 (ADP Ribosylation Factor Like GTPase 2) • PFKFB4 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4) • PFKP (Phosphofructokinase, Platelet) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
1m
Amino acid metabolism-related model for prognosis and immunity in gastric cancer. (PubMed, Amino Acids)
Our AAMRGs prognostic model reveals AAMRGs as independent prognostic factors for GC, highlighting their association with prognosis and immune cell infiltration. These findings provide important insights for improving survival outcomes and advancing immunotherapy strategies in GC.
Journal • IO biomarker
|
MTHFR (Methylenetetrahydrofolate Reductase) • COL1A1 (Collagen Type I Alpha 1 Chain) • PDK4 (Pyruvate Dehydrogenase Kinase 4) • KYNU (Kynureninase) • NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
2ms
Novel insights into the mechanism of formaldehyde-induced lung cancer: a network toxicology and molecular docking approach. (PubMed, Toxicol Mech Methods)
Single-cell RNA sequencing distribution analysis showed that ADH5 and ADH1B were significantly enriched in Fibroblasts cell clusters, and ADH7 was significantly enriched in Basal cells cell clusters. Our study provides key targets and pathways for understanding the complex molecular mechanisms by which FA affects lung cancer, reveals complex relationships that are difficult to find by traditional toxicological methods, and provides insights into strategies for preventing lung cancer caused by FA exposure.
Journal
|
ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
5ms
Decoding the cholesterol-apoptosis axis in HCC: a machine learning-based multi-omics integration and single-cell transcriptomic analysis. (PubMed, Discov Oncol)
Single-cell analysis identified six major cell types, providing a deeper understanding of the cellular heterogeneity within LIHC. In summarize, this study presents the first integrated apoptosis-cholesterol metabolic pathway-based six-gene prognostic model for LIHC, validated for robustness across multiple cohorts, which may facilitate personalized therapeutic strategies and refined risk assessment in clinical practice.
Journal
|
FABP5 (Fatty Acid Binding Protein 5) • HMGCS2 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 2) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
5ms
Prognostic modeling and immune infiltration analysis in hepatocellular carcinoma using glutathione metabolism-associated genes. (PubMed, Eur J Med Res)
In summary, this study established a prognostic risk model for HCC based on GSH metabolism-related genes, which could predict the prognosis and characterize immune infiltration status of HCC. This study may contribute to the identification of potential prognostic targets and the development of new clinical management strategies for HCC.
Journal • IO biomarker
|
CDCA8 (Cell Division Cycle Associated 8) • KIF20A (Kinesin Family Member 20A) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
5ms
Nanomaterial-assisted immunodiagnostic profiling and therapeutic targeting of hepatocellular carcinoma: from molecular biomarkers to clinical applications. (PubMed, Front Immunol)
By integrating transcriptomic and proteomic screening with epitope-level validation, we identified a novel panel of immunogenic biomarkers suitable for nanomaterial-enabled diagnostics in HCC. These findings support the translational potential of peptide-nano scaffold conjugates in developing minimally invasive, immune-responsive biosensing and therapeutic tools tailored for early-stage liver cancer management.
Journal
|
HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
6ms
Construction of a novel prognostic model for gastric cancer based on pharmacokinetics-related genes and comprehensive prognostic analysis. (PubMed, Front Genet)
We have developed and validated an innovative prognostic risk model for GC, revealing that elevated ADMERGs risk scores are indicative of unfavorable prognosis and diminished immunotherapy response. These findings furnish molecular evidence regarding the participation of ADMERGs in modulating the immune microenvironment and therapeutic responsiveness in GC.
PK/PD data • Journal • IO biomarker
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • CD4 (CD4 Molecule) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
6ms
Predicting the prognosis of hepatocellular carcinoma based on genes related to polyamine metabolism. (PubMed, PeerJ)
Single-cell analysis showed that G6PD and S100A9 were high-expressed mainly in hematopoietic progenitor cells (HPCs) and macrophages. In conclusion, this study screened four key genes based on PMRGs and constructed a risk model to effectively predict the prognosis of HCC, providing novel potential targets and theoretical basis for the molecular subtyping and individualized treatment of HCC.
Journal
|
S100A9 (S100 Calcium Binding Protein A9) • G6PD (Glucose-6-Phosphate Dehydrogenase) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
9ms
SPP1 promotes malignant characteristics and drug resistance in hepatocellular carcinoma by activating fatty acid metabolic pathway. (PubMed, Funct Integr Genomics)
In vivo experiments showed that SPP1 knockdown inhibited tumor growth and fatty acid metabolism of HCC mice. In conclusion, SPP1 is a pivotal gene that influences HCC prognosis by enhancing malignancy and drug resistance through fatty acid metabolism.
Journal
|
SPP1 (Secreted Phosphoprotein 1) • ANXA10 (Annexin A10) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
9ms
In vivo CRISPR screening identifies POU3F3 as a novel regulator of ferroptosis resistance in hepatocellular carcinoma via retinoic acid signaling. (PubMed, Cell Commun Signal)
According to the results, POU3F3 acts as a protective regulator against sorafenib-induced ferroptosis in HCC cells by enhancing the transcription of multiple retinoic acid metabolism genes and promoting retinoic acid production. The POU3F3 inhibitor, rosarin, shows potential as an ideal candidate for overcoming sorafenib resistance in HCC.
Preclinical • Journal
|
ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • ALDH1A3 (Aldehyde Dehydrogenase 1 Family Member A3) • FABP5 (Fatty Acid Binding Protein 5) • RBP1 (Retinol Binding Protein 1) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)
|
sorafenib • RSL3
11ms
From genes to therapy: a lipid Metabolism-Related genetic risk model predicts HCC outcomes and enhances immunotherapy. (PubMed, BMC Cancer)
The risk model constructed using lipid metabolism-related genes could effectively predict prognosis and was related to the immunosuppressive microenvironment and ICB immunotherapy. The hub genes related to the risk model were potential therapeutic targets.
Journal • IO biomarker
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • CDK1 (Cyclin-dependent kinase 1) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • ACACA (Acetyl-CoA Carboxylase Alpha) • LPCAT1 (Lysophosphatidylcholine Acyltransferase 1) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)